Education
About Us
Working with TipRanks
Follow Us
Immunicum AB (SE:IMMU)
:IMMU
Top Page
Immunicum AB
(Frankfurt:IMMU)
32Underperform
Immunicum AB (IMMU) vs. S&P 500 (SPY)
Market Cap
kr269.93M
Dividend YieldN/A
Average Volume (3M)22.07K
Price to Earnings (P/E)―
Beta (1Y)0.91
Revenue GrowthN/A
EPS Growth21.85%
CountrySE
Employees28
SectorHealthcare
Sector Strength38
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.60
Shares Outstanding50,359,577
10 Day Avg. Volume20,987
30 Day Avg. Volume22,074
Financial Highlights & Ratios
PEG Ratio-0.20
Price to Book (P/B)0.58
Price to Sales (P/S)0.00
P/FCF Ratio-4.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Immunicum AB Business Overview & Revenue Model
Company DescriptionMendus AB (publ), a biopharmaceutical company, develops immunotherapies and relapse vaccines for the treatment of cancer. Its lead product is ilixadencel, which is in Phase II MERECA clinical trial for the treatment of kidney cancer; and Phase I/II clinical trial to treat liver cancer and gastrointestinal stromal tumors. The company's products also comprise DCP-001, which is in Phase II ADVANCE-II clinical trial for the treatment of acute myeloid leukemia; and Phase I/II ALISON clinical trial for the treatment of ovarian cancers. It has a research collaboration with PCI Biotech Holding ASA for novel cancer vaccination treatment; and with Icahn School of Medicine at Mount Sinai. The company was formerly known as Immunicum AB (publ) and changed its name to Mendus AB (publ) in June 2022. Mendus AB (publ) was incorporated in 2002 and is headquartered in Stockholm, Sweden.
How the Company Makes MoneyImmunicum AB generates revenue through the development and commercialization of its proprietary immune therapies. The company's primary revenue stream comes from partnerships and collaborations with larger pharmaceutical and biotechnology firms that are interested in co-developing or licensing its technology. These partnerships often involve milestone payments and royalties based on the success and commercialization of the therapies. Additionally, Immunicum may receive funding from grants or governmental support for innovative research in immuno-oncology. The company’s revenue model is heavily reliant on the successful progression of its therapies through clinical trials and subsequent market approval.
Immunicum AB Financial Statement Overview
Summary
Income Statement
Balance Sheet
Cash Flow
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 3.41M | 28.49M | 3.00M | 6.00K | 0.00 | 16.67M | Gross Profit |
| 1.79M | 28.49M | -1.85M | -1.84M | -1.77M | 15.03M | EBIT |
| -133.34M | -100.65M | -133.68M | -130.10M | -86.03M | -132.32M | EBITDA |
| -120.68M | -97.85M | -128.67M | -128.28M | -84.25M | -43.22M | Net Income Common Stockholders |
| -128.40M | -101.62M | -136.99M | -136.69M | -92.47M | -135.71M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 393.36M | 120.78M | 41.85M | 155.31M | 167.64M | 296.81M | Total Assets |
| 398.55M | 755.95M | 620.39M | 720.98M | 728.66M | 303.83M | Total Debt |
| 850.00K | 24.49M | 78.16M | 36.98M | 35.04M | 850.00K | Net Debt |
| -392.51M | -96.29M | 36.31M | -118.34M | -132.60M | -295.96M | Total Liabilities |
| 21.65M | 51.23M | 105.95M | 64.24M | 67.57M | 31.05M | Stockholders Equity |
| 376.90M | 704.73M | 514.44M | 656.74M | 661.09M | 272.78M |
| Cash Flow | Free Cash Flow | ||||
| -81.51M | -164.58M | -121.43M | -139.39M | -57.09M | -146.62M | Operating Cash Flow |
| -79.67M | -162.76M | -109.33M | -138.03M | -56.63M | -145.81M | Investing Cash Flow |
| -1.58M | -442.00K | -12.32M | -1.36M | 157.30M | -251.00K | Financing Cash Flow |
| 61.51M | 242.10M | 8.19M | 127.03M | 50.90M | 756.00K |
Immunicum AB Technical Analysis
Negative
5.09
Price Trends
5.95
Negative
6.99
Negative
7.79
Negative
Market Momentum
-0.14
Negative
43.90
Neutral
9.02
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:IMMU, the sentiment is Negative. The current price of 5.09 is below the 20-day moving average (MA) of 5.28, below the 50-day MA of 5.95, and below the 200-day MA of 7.79, indicating a bearish trend. The MACD of -0.14 indicates Negative momentum. The RSI at 43.90 is Neutral, neither overbought nor oversold. The STOCH value of 9.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:IMMU.
Immunicum AB Peers Comparison
Overall Rating
UnderperformOutperform
Sector (52)
Financial Indicators
Performance Comparison
SE:IMMU
Immunicum AB
5.09
-3.85
-43.06%
DE:7XB
Xbrane Biopharma AB
0.02
0.00
0.00%
DE:5IU
Isofol Medical AB
0.12
0.06
100.00%
DE:1XT
Xintela AB
0.03
0.02
200.00%
DE:2E9
Intervacc AB
0.08
-0.20
-71.43%
DE:5LH0
Guard Therapeutics International AB
1.32
-1.69
-56.15%
Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.